

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: _____ (use as many sheets as necessary)			Complete if Known Application Number 10/781,263 Filing Date 2/19/2004 First Named Inventor Yoshiyuki INADA Art Unit 1626 Examiner Name SJY Loewe Deborah G. Lambkin Attorney Docket Number 087147-0494		
Sheet	1	of	2		



U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
SL	C1	EP 052575 A1	09/09/1992	Merck & Co., Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
SL	C2	Opposition Brief dated February 6, 2004, submitted by Strawman Ltd. in Opposition Proceedings of EP 0753301 (21 pgs.).	
	C3	Opposition Brief dated February 6, 2004, submitted by Hexal AG in Opposition Proceedings of EP 0753301 (19 pgs.) with English translation (13 pgs.).	
	C4	Petition dated July 14, 2005 submitted by Takeda Pharmaceutical Company Limited in Opposition Proceedings of EP 0753301 (15 pgs.).	
	C5	Petition dated April 24, 2006, submitted by Hexal AG in Opposition Proceedings of EP 0753301 (5 pgs.) with English translation (7 pgs.).	
	C6	Petition dated September 12, 2006, submitted by Hexal AG in Opposition Proceedings of EP 0753301 (2 pgs.) and English translation (2 pgs.).	
	C7	Petition dated February 12, 2007, submitted by Strawman Ltd. in Opposition Proceedings of EP 0753301 (5 pgs.).	
	C8	Petition dated June 18, 2007, submitted by Hexal AG in Opposition Proceedings of EP 0753301 (5 pgs.) and English translation (5 pgs.).	

Examiner Signature	/Sun Jae Y. Loewe/	Date Considered	3-10-2008
--------------------	--------------------	-----------------	-----------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 061.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/781,263
Date Submitted: _____ (use as many sheets as necessary)		Filing Date	2/19/2004
		First Named Inventor	Yoshiyuki INADA
		Art Unit	1626
		Examiner Name	Deborah C. Lambkin
		Attorney Docket Number	087147-0494
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
SL	C9	Petition dated June 19, 2007, submitted by Strawman Ltd. in Opposition Proceedings of EP 0753301 (15 pgs.).	
	C10	Petition dated June 19, 2007, submitted by Takeda Pharmaceutical Company Limited in Opposition Proceedings of EP 0753301 (9 pgs.).	
	C11	Decision dated September 18, 2007, rejecting the Opposition of EP 0753301 (11 pgs.).	
	C12	KAPLAN, Norman M. M.D., Clinical Hypertension, 1990, p. 239 (3 pgs.).	
	C13	Summary of product characteristics for Amias (candesartan cilexetil) of Takeda UK Ltd., updated 11/16/2006, and obtained from website 12/18/2006 (http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?docum...) (14 pgs.)	
	C14	"Example for Side Effects" and "Comparative Example" data filed in Opposition Proceedings of EP 0753301 on 7/14/2005 by patent owner (2 pgs.);	
	C15	FDA Approval letter and package for hydrochlorothiazide tablets USP 25 & 50 mg of Barr Laboratories, Inc., 1974 (8 pgs.).	
	C16	ABPI Data Sheet Compendium, 1991/1992, entry for hydrochlorothiazide tablets, p. 290-291 (5 pgs.).	
	C17	KAPLAN, Norman M., Clinical Hypertension, 1990, pp. 71-73, 189, 190-193 (11 pgs.).	
	C18	SCALBERT et al., "Interaction between an angiotensin converting enzyme inhibitor, perindopril, and a thiazide diuretic in the spontaneously hypertensive rat," Can. J. Cardiol., May 4, 1992, 8(4):381-386.	
	C19	Prof. Dr. M. Tauchert, Curriculum and Expert Opinion, filed on June 18, 2007, in Opposition Proceedings of EP 0753301 (7 pgs.) with English translation (9 pgs.).	
	C20	WOLLAM et al., "Antihypertensive Drugs: Clinical Pharmacology and Therapeutic Use," Drugs, 1977, 14:420-460.	
	C21	JAHNECKE, J., "Stufenplan der Hochdrucktherapie," Verh. Dtsch. Ges. Kreislaufforsch., 1977, 43:115-119 with English summary (2 pgs.)	
	C22	KAPLAN et al., "Antihypertensive Drugs in Combination," Arch. Intern. Med., May 1975, 135:660-663.	

Examiner Signature	/Sun Jae Y. Loewe/	Date Considered	3-10-2008
--------------------	--------------------	-----------------	-----------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.